Adverum Biotechnologies Inc expected to post a loss of $1.31 a share - Earnings Preview

* Adverum Biotechnologies Inc is expected to show a rise in quarterly revenue when it reports results for the period ending December 31 2024

* The Redwood City California-based company is expected to report revenue of $87.5 thousand, according to the mean estimate from 6 analysts, based on LSEG data.

* ​LSEG's mean analyst estimate for Adverum Biotechnologies Inc is for a loss of $1.31 per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts had risen by about 8.8% in the last three months. ​

* Wall Street's median 12-month price target for Adverum Biotechnologies Inc is $30.00​, above​ its last closing price of $7.72. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jan. 1 0001 -1.29 -1.31 -1.30 Beat 0.5

Jun. 30 0001 -1.44 -1.47 -0.89 Beat 39.4

Mar. 31 2024 -1.55 -1.40 -1.50 Missed -6.8​

Dec. 31 2023 -3.35 -3.37 -2.30 Beat 31.7

​​Sep. -3.06 -3.15 -3.30 Missed -4.7

30 2023

Jun. 30 2023 -3.12 -3.29 -3.10 Beat 5.7​

Mar. 31 2023 -3.20 -3.20 -2.90 Beat 9.5

Dec. 31 2022 -3.72 -3.62 -3.30 Beat 8.9

This summary was machine generated November 6 at 13:49 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)